Details for Patent: 12,337,002
✉ Email this page to a colleague
Which drugs does patent 12,337,002 protect, and when does it expire?
Patent 12,337,002 protects WINLEVI and is included in one NDA.
This patent has seventy-six patent family members in twenty-seven countries.
Summary for Patent: 12,337,002
| Title: | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
| Abstract: | The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate. |
| Inventor(s): | Mauro Ajani, Luigi Moro |
| Assignee: | Cosmo SpA , Cassiopea SpA |
| Application Number: | US18/057,031 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,337,002 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 12,337,002
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | WINLEVI | clascoterone | CREAM;TOPICAL | 213433-001 | Aug 26, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17ALPHA-PROPIONATE | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,337,002
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2503005 | ⤷ Start Trial | C20250037 | Finland | ⤷ Start Trial |
| European Patent Office | 2503005 | ⤷ Start Trial | CA 2025 00047 | Denmark | ⤷ Start Trial |
| European Patent Office | 2503005 | ⤷ Start Trial | 301358 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2503005 | ⤷ Start Trial | 2025C/551 | Belgium | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
